CRISPR/Cas9 在癌症治疗中的应用：临床转化、机制策略与治疗方向

CRISPR/Cas9 in cancer therapy: clinical translation, mechanistic strategies, and therapeutic directions.

利用 CAR-NK 细胞对抗多发性骨髓瘤：当前格局与未来方向

Harnessing CAR-NK cells against multiple myeloma: current landscape and future directions.

CAR-NK 疗法正从一种有前景的概念演变为针对 MM 的现实治疗平台。

CAR 疗法在肿瘤与自身免疫领域的演进：机制见解与治疗创新

The evolution of CAR therapies across oncology and autoimmunity: mechanistic insights and therapeutic innovations.

用于多发性骨髓瘤的完全非病毒 1XX 增强型 BCMA CAR-T 细胞治疗的开发

Development of a Fully Non-Viral 1XX-enhanced BCMA CAR-T Cell Therapy for Multiple Myeloma.

下一代肿瘤免疫治疗：CAR-T 细胞治疗的前景

Next-generation cancer immunotherapy: the promise of CAR T-Cell therapy.

靶向肿瘤坏死因子受体超家族成员 8 (CD30) 的 CAR-T 细胞治疗用于复发/难治性间变性大细胞淋巴瘤：原理、策略和新兴临床证据

Chimeric Antigen Receptor T‑Cell Therapy Targeting Tumor Necrosis Factor Receptor Superfamily Member 8 (CD30) for Relapsed or Refractory Anaplastic La

结合 CRISPR/Cas9 介导的 TRAC 敲除与基于 mRNA 的 CAR 表达实现异体 CAR-T 细胞的灵活制备

Combining CRISPR/Cas9-mediated TRAC knockout with mRNA-based CAR expression enables flexible generation of allogeneic CAR T cells.

这些发现建立了一个利用 mRNA 技术生产同种异体 CAR-T 细胞的模块化平台，为快速、按需的 CAR-T 细胞疗法提供了一种实用方法。

浆细胞疾病细胞免疫治疗的 2025 年更新

2025 Update of Cellular Immunotherapy for Plasma Cell Disorders.

CAR-T 细胞治疗：革新肿瘤治疗

Chimeric antigen receptor T cell therapy: Revolutionizing cancer treatment.

巨噬细胞中 CRISPR 敲低 CHIP 基因驱动 CAR-T 细胞治疗中炎症细胞因子产生增加

CRISPR Knockdown of CHIP Genes in Macrophages Drives Increased Production of Inflammatory Cytokines in CAR-T Cell Therapy.